YUCAIPA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (Pink Sheets: IGTG), a new medical device manufacturer, announced today that the Taiwan registration process for Oxyview(R) with their exclusive Asian distributor, Progressive International Holding Company Ltd., has been initiated. Progressive International Holding Company is working directly with the Taipei Economic and Cultural Representative Office in the United States for the Certificate to Foreign Government.
Progressive International Holding Company has been a strong presence in the Asian healthcare market during the past twenty years. In view of China as one of the fastest growing countries in the world and with the rising demand for healthcare products inland, Progressive International Holding Company has introduced Oxyview(R) to the Taiwan, China, Japan and Korea medical market. Not only does Progressive International Holding Company want to pursue a leading role in the diagnostic, medical device and POC markets in China, but also has a strong position in Taiwan. With a stronghold of Primus Medical (Shanghai) and Taiwan's experience, Progressive International Holding Company shall have a strong and unique position in the Asian healthcare market to sell Oxyview(R).
"Ingen Technologies is working close with Progressive International
Holding Company to complete the registration process for Oxyview(R). This
process is similar to the FDA and DHS compliances that Ingen and Oxyview(R)
have already successfully completed last year," said Scott Sand, Chairman
For more information please visit: http://www.wallst.net/superstocks/superstocks_profile.asp?ticker=igtg
About Ingen Technologies, Inc.
Ingen Technologies is a new medical device manufacturer that owns
proprietary intellectual property for the growing respiratory market. The
Oxyview(R) was recently assigned Class-I with the Food & Drug
Administration. The Company has several other related products being
scheduled for release during 2008 and will continue to roll-out additional
medical products during the next several years. The principals and
management of Ingen Technologies are committed to the success of the
company and have invested more than $5 million of their own money towards
R&D and the manufacturing of proprietary biotech products for the medical
market. The Company owns multiple Patents and Trademarks in the United
States, European Communities, Japan, and the Peoples Republic of China. The
Company has had revenues since 2002 with their Secure Balance(R) products,
and has recently released their new Oxyview(R) product worldwide through
two of the world's largest home health care distributors in the United
States, Asia and 80 other countries. Further, new markets in Asia have been
recently secured with monthly deliveries of 10,000 Oxyview(R) units. The
Company's respiratory product line will benefit from the $4 billion
respiratory market that will grow to $6 billion by 2010. With 8-9% of
Americans over 65 that have a respiratory illness and require home oxygen
therapy, the world market is 10-12% and offers a growing revenue stream for
the company. The elderly population in the United States will double
between 2010 and 2015, increasing the number of respiratory illnesses and
increasing the need for Oxyview(R) and OxyAlert(R).
For more information, visit: http://www.ingen-tech.com
Contact: Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc. - Administrative Office
35193 Avenue "A", Suite-C
Yucaipa, California 92399
Phone: (909) 790-7180
Fax: (909) 795-6340
A Member of the Better Business Bureau
A Member of the Chamber of Commerce
A Licensed Business in the City of Yucaipa
A Certified Manufacturer with FDA/DHS
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
|SOURCE Ingen Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved